To discover and develop breakthrough antibody-based cancer therapeutics by integrating innovative technologies    

Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Through its robust pipeline of first-in-class candidates and proprietary ADC platform, Igenica is accelerating the development and delivery of effective therapies that hold the potential to change the face of cancer treatment.

Year Invested: 2012
Location: Burlingame, Calif.

Recent News

October 28, 2015
Igenica Biotherapeutics Enters Into a Strategic Oncology Research Agreement with MedImmune

October 23, 2014
Igenica Biotherapeutics to Present New Data on Proprietary SNAP Antibody Drug Conjugate Technology at Upcoming World ADC Summit

August 7, 2014
Igenica Biotherapeutics Awarded SBIR Grant for Next Generation Antibody Drug Conjugate Technology

Read More News

Associated Team Members

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner